Arkansas opioid case gives UAE clinics 3 controlled-medicine checks to audit

Northwest Arkansas Democrat-Gazette reported that an Arkansas panel revoked the medical licence of Clarksville psychiatrist Dr. Marion M. Stowers over prescriptions to opioid use disorder patients, a case that UAE clinic operators should read as a controlled-medicine governance warning rather than a U.S. local disciplinary story.

The highest-stakes readers are COOs, medical directors and insurers. In Dubai, any clinic prescribing narcotic, controlled or semi-controlled medicines sits under Dubai Health Authority (DHA) rules and the national controlled-medication platform. In Abu Dhabi and Al Ain, the same risk is overseen by the Department of Health Abu Dhabi (DOH). In the northern emirates, the relevant regulator is the Ministry of Health and Prevention (MOHAP).

What happened in Arkansas

The Northwest Arkansas Democrat-Gazette report names a psychiatrist in Clarksville, Arkansas and ties the action to prescriptions for patients with opioid use disorder. The Arkansas State Medical Board public licence-action page lists Marion Middlekamp Stowers, M.D., licence E-0065, with an Emergency Order of Suspension dated 1 September 2026.

That distinction matters. The newspaper reports a revocation decision. The regulator's live public list, checked on 3 October 2026, still shows the earlier emergency suspension entry. UAE compliance teams should treat the case as a reminder to reconcile media reports, regulator registers and internal credentialing files before changing provider status, payer privileges or patient access.

Why it matters in the UAE

The UAE already has a tighter formal framework for controlled medicines than many outpatient markets. DHA says its Drug Control section governs medication-control processes and issues approvals for private healthcare facilities and professionals licensed by DHA. DHA circular CIR-2019-00000231 required DHA-licensed physicians and pharmacists dealing with narcotic, controlled and semi-controlled medicines to use the unified controlled-prescription platform from 19 May 2019.

DOH told Abu Dhabi healthcare and pharmaceutical facilities that the inventory-management module of the national platform for narcotic, controlled and semi-controlled medications would be activated from 15 July 2024. MOHAP's national guidance says narcotic, psychotropic and other controlled medicines are not freely available in the UAE and must follow official prescription controls.

• COOs should check that each controlled-medicine prescriber has active platform access, a current emirate licence and documented prescribing privileges.
• Medical directors should audit opioid-use-disorder files for diagnosis, consent, medication rationale, follow-up interval and documented risk review.
• CFOs and insurers should match controlled-medicine claims against pre-authorisation rules, network status and documented eligibility before payment.
• CIOs should confirm that EHR, e-prescribing and pharmacy records can produce a patient-level audit trail within one business day.

One check is especially practical. The UAE Government portal states that controlled medicines must be prescribed on the official psychotropic prescription form where required. A DOH controlled-medicines standard cites Ministerial Decree No. 888 of 2016 and says the validity of a narcotic or psychotropic medicinal prescription is no more than three days from issue.

What clinics and insurers should do now

Dubai clinics should start with the DHA Sheryan licence record, the DHA Drug Control requirements and the national platform account for each relevant prescriber. Abu Dhabi operators should use DOH licensing records and controlled-medicine platform data. Northern-emirates clinics should check MOHAP facility and professional licensing records before allowing any doctor to prescribe controlled medicines.

Patients face a different risk. When a prescriber loses authority, continuity of treatment can break within days. UAE clinics offering psychiatry, pain management or addiction-related care should keep a written handover process for controlled medicines, including referral options, emergency coverage, medication reconciliation and insurer approval status with Daman, Thiqa or Sukoon where those payers are part of the patient's plan.

Operators should avoid quoting generic AED prices for controlled-medicine visits unless the number comes from their own tariff, insurer contract or regulator-approved price file. A safer benchmark is operational: list every prescriber, every controlled drug category, every platform account and every insurer rule in one register, then review it monthly.

For patients and clinic teams checking licensed providers in the UAE, start with the UAE Open Healthcare Directory and verify the final licence status with DHA, DOH or MOHAP before booking, referring or reimbursing care.